Case Presentations
Case Histories:
Patients receiving treatment guided by TumorGraft testing have responded to their individualized treatment, and seen a reduction in the size of their tumor for with durable remissions1. Tumors that have been treated successfully using TumorGraft testing include cancers of the colon, pancreas, stomach, esophagus, lung, and breast, as well as sarcomas and others.
Treatments included single agent chemotherapy drugs, combination chemotherapy drugs, targeted biological drugs and investigational drugs in clinical trials. In many of these cases, Champions Oncology successfully identified several treatments that were used one after another to provide additional clinical benefits.
Real-World Results From Personalized TumorGrafts™
The Science in Action — Dean, 63, Metastatic Pancreatic Cancer
Treatment history:
Dean underwent extensive abdominal surgery to resect a cancer of the pancreas, but the cancer recurred 12 months after surgery. Dean was treated with the most common treatment (i.e., standard of care), the anticancer drug gemcitabine for four months until the cancer began to grow despite treatment.
What Champions Oncology found:
Based on TumorGraft testing, one of the treatments tested was mitomycin C – which is rarely used to treat pancreatic cancer. This treatment showed a significant response in the TumorGraft.
Example of Personalized TumorGraft™ results, showing how one treatment was more effective than the others tested. (This case was published in Molecular Cancer Therapeutics, Villarroel et al.)2
Targeted Treatment Results
Based on Personalized TumorGraft™ findings, Dean received three cycles of Mitomycin C. At the time he started Mitomycin C hisCA 19-9 was 98,000 (units/mL) and after three cycles it had normalized. His cancer went into complete remission lasting for three years — Dean is still alive today. The average survival of metastatic pancreatic cancer is approximately six to eight months.
Additional Case Studies:
Gastroesophageal cancer:
A 56-year-old male with metastatic gastroesophageal cancer who had 2 prior regimens (1)
The following demonstrates the TumorGraft response to drug-testing-informed treatment decisions.
Case study conclusions
- The patient responded to 4 courses of Champions Tumor Graft-guided therapy
- Survival lasted 32 months in late-line therapy. The patient died of an infection while the tumor had remained stable.
Metastatic Colorectal Cancer:
44-year-old female diagnosed with metastatic colorectal cancer who had 2 prior regimens
The following demonstrates the TumorGraft response to drug-testing-informed treatment decisions.
- Patient’s pelvic tumor regressed by 60% following Irinotecan monotherapy (partial response) even though the pt had received FOLFIRI in the past
- The patient had resolution of the hydronephrosis
- Patient had a partial response lasting longer than 50 months
- Additional drug testing revealed that maximal response in the patients Tumorgraft™ was achieved with laptinib combined with capecitabine (4th line of treatment).
- Patient’s tumor regressed to a partial response, which lasted 6 additional months
Case study conclusions
- The TumorGraft revealed that the patient would respond best to one of the three combined treatments she received previously
- Patient responded to two courses of Champions-guided treatment
- Because the tumor had reoccurred and metastasized after FOLFIRI treatment, the patient would have likely never been retreated with irinotecan again if not for TumorGraft testing
Metastatic Leiomyosarcoma:
55-year-old female diagnosed with abdominal metastatic leiomyosarcoma who had 3 prior regimens
The following demonstrates the TumorGraft response to drug-testing-informed treatment decisions.
- Triple drug therapy, consisting of gemcitabine, docetaxel and bevacizumab) was selected for fourth-line treatment and resulted in a 50% reduction in tumor mass (partial response)
- Patient remained in partial response for 9 months
- Additional drug testing revealed that maximal response in the patients TumorGraft was achieved with capecitabine combined with temozolomide (5th line of treatment).
- This treatment was not a standardtreatment for leiomyosarcoma
- The patient’s tumor regressed (partial response) for 6 more months
Case study conclusions
- Patient responded to 2 courses of Champions-guided treatment
- One of the combinations found was novelfor the treatment of leiomyosarcoma
- Patient lived 15 months on late line therapy
Lung cancer:
50-year-old male diagnosed with stage IV non-small cell lung cancer who had received treatment with two prior chemotherapy regimens
The following demonstrates the TumorGraft response to drug-testing-informed treatment decisions.
- The patient’s physician elected to treat patient with 3rd- line treatment, consisting of sorafenib, bevacizumab and irinotecan, based on TumorGraft results
- Patient’s tumor regressed (partial response) for 9 months
- Triple therapy was then discontinued due to side effects
- Sorafenib alone was continued and delivered another 6 months of remission
Case study conclusions
- Patient responded to one course of Champions-guided treatment
- Patient lived 15 months on late line therapy